Description
Erythropoietin alfa is recombinant human erythropoietin (EPO). It is expressed in Chinese hamster ovary cells and has a 165 amino acid sequence identical to that of human urinary EPO; the two are indistinguishable on the basis of functional assays. The apparent molecular weight of erythropoietin is about 30,400 daltons.
IndicationsÂ
Erythropoietin alfa is an erythropoiesis-stimulating agent (ESA) indicated for:
Treatment of anemia due to:
Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
Zidovudine in HIV-infected patients.
The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
Dosage & Administration
- Predialysis and haemodialysis: Initial: 50 IU/kg 3 times/wk;
- Peritoneal dialysis: 50 IU/kg twice wkly.
Anaemia in zidovudine-treated HIV-infected patients As epoetin alfa: Initial: 100 IU/kg 3 times/wk for 8 wk. Max: 300 IU/kg 3 times/wk.
Anaemia related to non-myeloid malignant disease chemotherapy As epoetin alfa or zeta: Initial: 150 IU/kg 3 times/wk, up to 300 IU/kg 3 times/wk.
Anaemia of chronic renal failure:
- Child: As epoetin alfa: Initially, 50 IU/kg 3 times wkly. May increase dose at 4 wkly intervals in increments of 25 IU/kg 3 times wkly until a target haemoglobin concentration of 9.5-11 g/100 mL is reached. Usual maintenance dose: 30 kg: 90-300 IU/kg/wk.
Reviews
There are no reviews yet.